Serina presents POZ-lipid LNP data showing no immune response in rats, solving PEG antibody issue

Serina Therapeutics, Inc.

POZ-lipid did not trigger IgM or IgG response after repeat dosing in rats in a vaccine format.
PEG-lipid standard elicited a strong, boosted antibody response under same conditions.
Anti-PEG antibodies linked to anaphylaxis in mRNA vaccines; POZ-lipid offers immune-silent alternative.
Data presented at 4th LNP Formulation & Process Development Summit on April 15, 2025.
Discovery could enable safer LNP formulations for gene therapy and RNA medicines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.